Three medical procedures covered with evidence development in Switzerland

10

Jan 2018

According to the principle of trust, medical services including devices and in-vivo diagnostics are covered by Swiss statutory health insurance (SHI) scheme without formal health technology assessments (HTA). However, in case of doubt that a medical service is effective, appropriate and efficient, it can be reported to the Federal Office of Public Health (FOPH) who reviews the available evidence on effectiveness, appropriateness, and cost-effectiveness of the method. The Department of Home Affairs (EDI) takes the final decision about the coverage of the service in the form of one of three possible outcomes:

•          Yes – continued coverage

•          No – exclusion from coverage

•          Yes, in evaluation – coverage while further evidence is collected

The status “Yes, in evaluation” can be connected to conditions as to lead a patient-based register or that reimbursement is limited to specific indications, centers or medical specialists. The status is set for a specific period which is extended until evidence is complete and can be considered as coverage with evidence development (CED) scheme.

On January 1st of 2018, this status was given to following medical services:

  • Positron emission tomography (PET, PET / CT) in the question "Massaging", according to the clinical guidelines of the SGNM, chapter 2.0, dated April 28, 2011 on FDG-PET. Status valid until 31.12.2018
  • Positron emission tomography (PET, PET / CT) using 18F-fluorocholine to clarify biochemically proven recurrence (PSA increase) of a prostate carcinoma. Status valid until 31.12.2018
  • Ambulatory stereotactic radiotherapy (photons) of exudative age-related macular degeneration if conditions below are met. Status valid until 30.6.2020
    • Choroidal neovascularization (CNV) with signs of activity such as intraretinal fluid or hemorrhage
    • Ongoing anti-VEGF therapy over a period of at least six months and thus exclusion of an under-treatment
    • No change in CNV activity status despite intensive injection therapy and no expected decline in the need for a high frequency of treatment in the future
    • Diameter of CNV maximal 4 mm (center maximally 3 mm away from the fovea)

The first two services (positron emission tomography) were given the CED-status previously and it was now renewed until the end of the year. Stereotactic radiotherapy is under CED for the first time in Switzerland.

Decisions by the Department of Home Affairs (EDI) about the coverage of medical services are documented in Annex 1 of the health care benefit ordinance (KLV).

Subscribe to our newsletter delivered every second week not to miss important reimbursement information.

The latest related news

28

Jul 2021

On July 01, 2021, NHS England published an update of the Specialized Services Policy Pipeline (covering March 21, 2021 - June 21, 2021). One new Clinical Commissioning Policy related to radiotherapy was published. Three new policies were added to the work program; however, all related to pharmaceuticals only. The status of ongoing policies was updated as well.

Read more

26

Jul 2021

The revised EBM (German Uniform Evaluation Standard) catalog came into force on July 1, 2021. Three biomarker tests in breast cancer, a number of services related to cryopreservation of egg and sperm cells in young cancer patients, new services dedicated to prenatal testing of the fetal rhesus factor, services concerning the delivery of brachytherapy in prostate cancer were introduced.

Read more

22

Jul 2021

On June 30, 2021, the Swiss Federal Council announced that the TARDOC outpatient tariff structure, presented by the association of insurers curafutura and the Swiss Medical Association (FMH), cannot be approved at this point. The Federal Council found the TARDOC tariff structure to have many drawbacks. Curafutura released an announcement in which they state that they will continue working on the TARDOC tariff structure and will try to implement as many changes as possible, according to the FOPH recommendations. This means that the TARDOC tariff structure is not likely to be implemented before January 2023.

Read more

19

Jul 2021

On June 24, 2021, the list of awarded PHRC and PRME projects, submitted in 2020, was published. A total of 137 PHRC and nine PRME projects were awarded, and they concern various technology groups, such as gynecology, nephrology, neurology, cardiovascular, etc.

Read more

05

Jul 2021

On July 1, 2021, the updated version of the Swiss Services Ordinance (KLV/OPre) came into force. The changes concern the List of explicitly evaluated services (Annex 1 of KLV/OPre), the List of medical aids (Annex 2 of KLV/OPre), and the List of Analyses (Annex 3 of KLV/OPre).

Read more